کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5529823 1401708 2017 6 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Esophageal cancerMulti-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer
ترجمه فارسی عنوان
سرطان مری - تحلیلی چندانی در مورد استفاده از روش های پرتو درمانی و نتایج پس از عمل شیمیدرمانی نئوادجوانانت در سرطان مری
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی تحقیقات سرطان
چکیده انگلیسی

PurposeRelative radiation dose exposure to vital organs in the thorax could influence clinical outcomes in esophageal cancer (EC). We assessed whether the type of radiation therapy (RT) modality used was associated with postoperative outcomes after neoadjuvant chemoradiation (nCRT).Patients and methodsContemporary data from 580 EC patients treated with nCRT at 3 academic institutions from 2007 to 2013 were reviewed. 3D conformal RT (3D), intensity modulated RT (IMRT) and proton beam therapy (PBT) were used for 214 (37%), 255 (44%), and 111 (19%) patients, respectively. Postoperative outcomes included pulmonary, GI, cardiac, wound healing complications, length of in-hospital stay (LOS), and 90-day postoperative mortality. Cox model fits, and log-rank tests both with and without Inverse Probability of treatment Weighting (IPW) were used to correct for bias due to non-randomization.ResultsRT modality was significantly associated with the incidence of pulmonary, cardiac and wound complications, which also bore out on multivariate analysis. Mean LOS was also significantly associated with treatment modality (13.2 days for 3D (95%CI 11.7-14.7), 11.6 days for IMRT (95%CI 10.9-12.7), and 9.3 days for PBT (95%CI 8.2-10.3) (p < 0.0001)). The 90 day postoperative mortality rates were 4.2%, 4.3%, and 0.9%, respectively, for 3D, IMRT and PBT (p = 0.264).ConclusionsAdvanced RT technologies (IMRT and PBT) were associated with significantly reduced rate of postoperative complications and LOS compared to 3D, with PBT displaying the greatest benefit in a number of clinical endpoints. Ongoing prospective randomized trial will be needed to validate these results.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Radiotherapy and Oncology - Volume 123, Issue 3, June 2017, Pages 376-381
نویسندگان
, , , , , , , , , , , , , , ,